Synthesis of (E)-7-arylidene-5-(hydroxy(aryl)methyl)bicyclo[3.2.0] heptan-6-one derivatives as anti-cancer agents
7,7-Dichlorobicyclo [3.2.0]heptan-6-one was prepared by adding dichloroketene to cyclopentene. Reduction of 7,7-dichlorobicyclo[3.2.0]heptan-6-one with Zn in acetic acid afforded the bicyclo[3.2.0]heptan-6-one. (E)-7-Arylidene-5-(hydroxy(aryl)methyl)bicyclo [3.2.0]heptan-6-ones were synthesized by a...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Tokat Gaziosmanpasa University
2023-12-01
|
| Series: | Journal of New Results in Science |
| Subjects: | |
| Online Access: | https://dergipark.org.tr/en/download/article-file/3435738 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | 7,7-Dichlorobicyclo [3.2.0]heptan-6-one was prepared by adding dichloroketene to cyclopentene. Reduction of 7,7-dichlorobicyclo[3.2.0]heptan-6-one with Zn in acetic acid afforded the bicyclo[3.2.0]heptan-6-one. (E)-7-Arylidene-5-(hydroxy(aryl)methyl)bicyclo [3.2.0]heptan-6-ones were synthesized by addition of related benzaldehydes to bicyclo[3.2.0]heptan-6-one. The anti-proliferative activities of synthesized compounds were elucidated against rat brain tumor (C6) and human cervical carcinoma cells (HeLa) cell lines. The most active compound was chloro derivative against C6 cell lines with IC50 = 2.45 μM value (5-FU, IC50 = 14.82 μM). Moreover, the most active compound was methyl derivative against HeLa cell lines with IC50 = 26.30 μM (5-FU, IC50 = 29.30 μM). |
|---|---|
| ISSN: | 1304-7981 |